BioLamina appoints Klaus Langhoff-Roos as new CEO.

BioLamina AB, a leading maker of reagents for stem and primary cells, today announces the appointment of Klaus Langhoff-Roos as Chief Executive Officer.

Klaus joins to bring his expertise in the stem cell field and leadership track record to support BioLamina through a period of accelerated scale-up and growth. The company is currently expanding its manufacturing capacity to meet customer demand, bolstered by the recent acquisition of a second clinical-grade manufacturing site. BioLamina has established strong industry partnerships and is further growing its customer base with the expansion of its commercial team in the company’s US headquarters in Cambridge, Massachusetts as well as on the West Coast.

Klaus brings over 15 years of experience leading international teams through successful life science scale-up and commercialization journeys. During his appointment as Head of Cell Therapy, Commercial at Novo Nordisk, he co-built the company’s cell therapy strategy across the value chain and helped create a product pipeline with three lead candidates moving towards first human dosing in large chronic disease areas. During his time as CEO of StemMedical, Klaus led the company as it took a stem cell-based treatment from lab to patient and scaled production of an emerging technology. Prior to engaging in the stem cell field, Klaus led the global commercialization of Novo Nordisk’s semaglutide molecule in metabolic disease (Ozempic® and Rybelsus®), establishing strong teams and external partnerships to drive market penetration in a mega-blockbuster therapeutic category.

 

Recently, positive proof-of-concept clinical trials in Parkinson’s Disease and Type 1 Diabetes demonstrate the potential of stem cell-based treatments to reverse disease and restore organ function when the body cannot do so itself. However, successful development and commercialization of these transformative therapeutics require the ability to produce truly functional cells at scale in a reproducible and compliant manner. The BioLamina team and technology are uniquely positioned to help industry and researchers with this challenge. I am looking forward to working with the team and their many dedicated partners to help unlock the potential of stem cell-based therapeutics and advanced cell-based disease models.

Klaus Langhoff-Roos, CEO of BioLamina

Following a rigorous selection process, the Board chose Klaus as the company’s new CEO due to his demonstrated abilities to lead companies of all sizes through complex scale-up challenges, his subject matter expertise in the stem cell space, and his fit with BioLamina’s dynamic, innovative, and customer-centric culture. We believe he possesses the right combination of skill, empathy, and conviction to support and accelerate BioLamina’s strategy to reach the company’s full potential. The Board would also like to take this opportunity to thank Veronica Byfield Sköld for her substantial contributions to the company throughout her CEO tenure. BioLamina’s shareholders, leadership and employees share a joint, long-term vision to make BioLamina a leading global provider of solutions for stem and primary cell culture to enable life-changing therapies.”.

Sophie Hagströmer, Chair of the Board at BioLamina,

For more information, please contact:

Camille Fournier-Sandberg, Head of Communications

Phone: +46 76 327 90 46
E-mail: info@biolamina.com

About BioLamina

BioLamina is a biotechnology company with a scientific base and heritage in matrix biology and cell culture research. It supports scientists who have struggled for decades to grow pluripotent stem cells and other primary cells in the lab. By providing tools for efficient and easy cell culture, BioLamina aims to ease the path towards safe and effective cell therapies and make better cell assays and models for increasing accuracy in drug discovery and development. The power of Biolaminin® substrates, developed by BioLamina, has been demonstrated in numerous publications, and they will continue to provide vital support to the stem cell community—from scientific concepts to clinical studies. Based in Stockholm (Sweden), the company currently employs 90 people. The company’s main shareholders include Bure Equity AB (via Bure Growth), the Tryggvason family (the company’s founders), Northislet AB, and Lauxera Capital Partners.